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CLINICAL INVESTIGATION
PRIME-HF: Novel Exercise for Older Patients with Heart
Failure. A Pilot Randomized Controlled Study
Catherine Giuliano, MAppSci,*† Itamar Levinger, PhD,*†‡ Sara Vogrin, MBiostat,‡§
Christopher James Neil, PhD,*†§a and Jason David Allen, PhD¶a
OBJECTIVES: To test the hypothesis that (1) older patients
with heart failure (HF) can tolerate COMBined moderate-
intensity aerobic and resistance training (COMBO), and
(2) 4 weeks of Peripheral Remodeling through Intermittent
Muscular Exercise (PRIME) before 4 weeks of COMBO
will improve aerobic capacity and muscle strength to a
greater extent than 8 weeks of COMBO.
DESIGN: Prospective randomized parallel open-label
blinded end point.
SETTING: Single-site Australian metropolitan hospital.
PARTICIPANTS: Nineteen adults (72.8  8.4 years of age)
with heart failure with reduced ejection fraction (HFrEF).
INTERVENTION: Participants were randomized to 4 weeks
of PRIME or COMBO (phase 1). All participants subse-
quently completed 4 weeks of COMBO (phase 2). Sessions
were twice a week for 60 minutes. PRIME is a low-mass,
high-repetition regime (40% one-repetition maximum
[1RM], eight strength exercises, 5 minutes each). COMBO
training involved combined aerobic (40%-60% of peak aero-
bic capacity [VO2peak], up to 20 minutes) and resistance train-
ing (50-70% 1RM, eight exercises, two sets of
10 repetitions).
MEASUREMENTS: We measured VO2peak, VO2 at anaer-
obic threshold (AT), and muscle voluntary contrac-
tion (MVC).
RESULTS: The PRIME group significantly increased VO2peak
after 8 weeks (2.4 mL/kg/min; 95% confidence interval
[CI] = .7-4.1; P = .004), whereas the COMBO group showed
minimal change (.2; 95% CI −1.5 to 1.8). This produced a
large between-group effect size of 1.0. VO2 at AT increased in
the PRIME group (1.6 mL/kg/min; 95% CI .0-3.2) but not in
the COMBO group (−1.2; 95% CI −2.9 to .4), producing a
large between-group effect size. Total MVC increased signifi-
cantly in both groups in comparison with baseline; however,
the change was larger in the COMBO group (effect size = .6).
CONCLUSION: Traditional exercise approaches (COMBO)
and PRIME improved strength. Only PRIME training pro-
duced statistically and clinically significant improvements to
aerobic capacity. Taken together, these findings support the
hypothesis that PRIME may have potential advantages for
older patients with HFrEF and could be a possible alternative
exercise modality. J Am Geriatr Soc 68:1954-1961, 2020.
Keywords: heart failure; exercise; strength; aerobic;
resistance
Chronic heart failure (CHF) is a complex syndromeaffecting 1% to 2% of Western populations,1 and
approximately 80% of patients are older than 60 years.2
Patients with CHF are characterized by shortness of breath,
fatigue, and exercise intolerance.3 Exercise rehabilitation is
considered a cornerstone intervention for people with CHF,
with guidelines recommending moderate-intensity aerobic
modalities,3,4 often in conjunction with resistance train-
ing.4-6 However, a key limitation of these guidelines is that
they arise largely from data involving a patient cohort
sometimes 2 decades younger (range = 51-81 years)7 than
the median age at diagnosis of CHF (77 years).7,8 Consider-
ing that older adults with CHF experience a high prevalence
of comorbidities, impaired functional capacity, reduced
muscle mass and strength, and a 5-year survival of
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25%,9-14 it is unclear whether they can actually tolerate
current exercise guidelines or gain functional benefits.
It was recently demonstrated that older individuals
with reduced peak aerobic capacity (VO2peak 15-20 mL/kg/
min) can benefit from a novel exercise regime known as
Peripheral Remodeling through Intermittent Muscular Exer-
cise (PRIME).15,16 In brief, PRIME offers a hybrid aerobic-
resistance program and was designed to address the periph-
eral tissue dysfunctions responsible for reduced VO2peak in
older adults, without imposing excess cardiovascular or
musculoskeletal strain.16 When PRIME is applied as a
bridging therapy to combined aerobic and resistance train-
ing, participants experience greater increases in aerobic
capacity, muscle strength, and physical function compared
with combined training alone. This approach may offer
potential advantages to older patients with central cardio-
vascular limitations; however, it is yet to be tested in clinical
populations.
The aim of the current study was to test the hypothesis
that (1) older patients with CHF can tolerate current exer-
cise recommendations involving COMBbined moderate-
intensity aerobic and resistance training (COMBO), and
(2) 4 weeks of PRIME training followed by 4 weeks of
COMBO will improve aerobic capacity and muscle strength




Participants were recruited from the Western Health Heart
Failure Clinic in Melbourne, Australia, following patient file
review and an in-person interview. Inclusion criteria were
(1) a diagnosis of HF with reduced ejection fraction
(HFrEF) as defined by European Society of Cardiology
Guidelines 2016,3 (2) age 65 years and older, and (3) mild
to moderate symptomatology (New York Heart Association
[NYHA] class II-III). Exclusion criteria included any abso-
lute contraindications to exercise for people with HFrEF,
and relative contraindications were adjudicated by the
study cardiologist. The algorithm for inclusion and exclu-
sion criteria is supplied in Supplementary Figure S1.
Patients meeting eligibility criteria were provided with infor-
mation and invited to participate in the trial. Those who
gave informed consent were scheduled for baseline testing
and screening. The research protocol was approved by
ethics committees from Melbourne Health and Victoria
University.
Experimental Design
We used a prospective randomized open-label blinded end-
point parallel-group design. Participants were randomized
to PRIME or COMBO training for an initial 4 weeks (phase
1). Following this, all participants completed 4 weeks of
COMBO training (phase 2). Participants were randomized
in a 1:1 ratio by an independent researcher (permuted block
randomization with block size of 4, stratified by sex, with
sequence saved in sequentially numbered opaque sealed
envelopes), with treatment allocation revealed after baseline
exercise testing. Outcomes were assessed at baseline,
4 weeks, and 8 weeks by a blinded assessor.
Outcome Measures
Aerobic Capacity
Peak aerobic capacity (VO2peak) was assessed using a symptom-
limited graded exercise test on a Lode Corival cycle ergometer,
with simultaneous 12-lead electrocardiogram. Heart rate (HR),
blood pressure (BP), and rating of perceived exertion (RPE)
were recorded throughout. The protocol began at 20 W and
increased by 10 W in 2-minute stages, and it was terminated
when the patient achieved more than 17 on the RPE scale and
was unable to continue cycling within 10 rpm of target cadence
or exhibited clinical signs and symptoms. The volume of oxygen
uptake (VO2) for each 10-second interval was calculated utiliz-
ing MedGraphics (Breezesuite CPX Ultim system) that was cali-
brated before each test.
Muscle Strength
Muscle strength was assessed using the three-repetition maxi-
mum (3RM) test, and then predicated 1RM was calculated
using standardized equations.17 Total muscle voluntary
contraction (total MVC) was considered as the sum of the cal-
culated 1RM for seven movements tested including chest
press, leg press, seated row, triceps pushdown, latissimus
pulldown, upright row, and hack squat.
Exercise Training Protocols
Training sessions were conducted twice per week for 8 weeks
and lasted approximately 60 minutes including warmup and
cooldown. Sessions were conducted at Victoria University
and Sunshine Hospital and supervised by an accredited exer-
cise physiologist. In the case of missed exercise sessions,
catch-up sessions were offered.
Phase I (PRIME)
The PRIME regime followed the protocol previously
described15,16 and was adjusted minimally for this study
group. The protocol included eight exercises of chest press,
leg press, seated row, triceps pushdown, latissimus dorsi
pulldown, upright row, hack squat, and calf raises, starting
at 40% of predicted 1RM and at a 2:1:2 movement tempo
(concentric: rest: eccentric). During each exercise, partici-
pants were allowed breaks as needed, with each for a mini-
mum of 30 seconds. Progression was made first by
decreasing the number of rest periods during each exercise.
When the patient could complete the whole duration of the
exercise (5 minutes) without rest, the load was increased by
approximately 10%.
Phase I (COMBO)
The COMBO protocol was based on exercise recommenda-
tions for patients with HFrEF and included both aerobic and
resistance exercises.5 The aerobic component began at 10 to
15 minutes at a target exercise intensity of 40% to 50% of
VO2peak, corresponding to an RPE of 11 to 13, progressing
gradually according to patient’s tolerance to 20 minutes.
Intensity was adjusted so the RPE remained in the target
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zones. The resistance component involved eight exercises,
two sets of 10 repetitions, initially prescribed at 50% to
60% 1RM. Thereafter, the load was increased by approxi-
mately 10% when the participant fell below an RPE target
range of 11 to 13.
Phase II
In phase II, all participants completed 4 weeks of identical
COMBO training as described earlier, with the starting intensity
for the aerobic and resistance components recalculated from
Figure 1. CONSORT flow diagram. AT, anaerobic threshold. COMBO, COMBined moderate-intensity aerobic and resistance
training; MVC, muscle voluntary contraction; PRIME, Peripheral Remodeling through Intermittent Muscular Exercise. [Color fig-
ure can be viewed at wileyonlinelibrary.com]
1956 GIULIANO ET AL. SEPTEMBER 2020-VOL. 68, NO. 9 JAGS
repeat exercise testing, prescribed at 50% to 60% of VO2peak
for the aerobic component and 60% to 70% 1RM for the resis-
tance component. Intensity was progressed according to RPE
zones.
RPE, HR, and BP were monitored before, during, and
after each training session. Individual HR and BP responses
were monitored by the supervising exercise physiologist for
signs of adverse responses or changing clinical status.
Volume load was calculated by repetitions [no.] ×
external load [kg], and aerobic exercise dose was estimated
using published metabolic equations.18
Statistics
Given the novel nature of this study, a convenience sample
size of 30 patients was used to estimate SD and effect sizes
to inform power for a future definitive trial. Descriptive
baseline characteristics data were presented as mean  SD
or frequency (percentage). Within-group comparisons
between baseline and 8 weeks for all outcomes were ana-
lyzed with paired sample t tests and reported as mean with
95% confidence intervals (CIs). Between-group compari-
sons of improvement over 8 weeks were analyzed by
Cohen’s d effect sizes (due to the pilot nature of the trial).
All statistical analyses were performed using GraphPad




Figure 1 presents the CONSORT flow diagram. Baseline
characteristics are presented in Table 1. For the entire cohort,
the mean age was 72.8  8.4 years and approximately 80%
of the participants were male. Baseline VO2peak was
13.5  3.2 mL/kg/min, body mass index was 31  4.8 kg/m2,
and mean ejection fraction was 31.6  7.0%. Common com-
orbidities were coronary artery disease (89%), hypertension
(74%), and type 2 diabetes mellitus (53%). During the trial,
all participants continued standard medical therapy as pre-
scribed by their physician.
Training
Adherence and Side Effects
During phase I, all participants achieved more than 75%
adherence (mean adherence = 97.3%  6.5). For phase II,
17 of 19 (89.5%) participants achieved more than 75%
adherence (mean adherence = 96.1%  12.2). In total,
292 of the 304 target exercise sessions (96%) were com-
pleted by the 19 participants, with an average weekly ses-
sion attendance of 1.6 sessions per week. None of the
19 participants who began the exercise interventions with-
drew from the study. Mean total time to program comple-
tion (including testing visits) was 11.4  1.4 weeks.
No major adverse events occurred during this study.
Minor events included one unrelated exacerbation of HF
and one unrelated chest infection. New musculoskeletal
complaints occurred in four of the PRIME participants
(on five occasions) and four of the COMBO participants
Table 1. Baseline Participant Characteristics- Descriptive
Statistics of Baseline Characteristics of Participants Who
Completed the Entire Interventiona
Characteristics All (19) PRIME (9) COMBO (10)
Age, y 72.8 (8.4) 68.1 (6.4) 77.0 (8.0)
Male, n (%) 15 (79) 7 (78) 8 (80)




LVEF (%) 31.6 (7.0) 31.1 (6.3) 32 (2.5)
Comorbidities, n (%)
CAD 17 (89) 8 (89) 9 (90)
HTN 14 (74) 6 (67) 8 (80)
DM Type 2 10 (53) 4 (44) 6 (60)
CKD 10 (53) 5 (56) 5 (50)
AF 9 (47) 4 (44) 5 (50)
PPM 5 (26) 2 (22) 3 (30)
AICD 3 (16) 1 (11) 2 (20)
COPD 2 (11) 0 (0) 2 (20)




17 (89) 8 (89) 9 (90)
Rockwood scale
≥5, n (%)




119.6 (15.2) 117.3 (13.4) 121.7 (17.0)
Diastolic BP,
mm Hg
67.5 (11.5) 64.2 (9.0) 70.5 (13.1)
HR, bpm 74.7 (10.3) 80.9 (8.2) 69.1 (9.0)




16 (84) 7 (78) 9 (90)
Diuretics 12 (63) 6 (67) 7 (70)
Aldosterone
antagonist
9 (47) 8 (89) 1 (10)
ACE inhibitor/ARB 11 (58) 7 (78) 4 (40)
Digoxin 2 (11) 2 (11) 0 (0)
>10 medications 3 (16) 3 (33) 0 (0)
Performance indicators
Peak VO2, mL/kg/min 13.5 (3.2) 13.1 (3.3) 13.3 (3.2)
Total exercise
time, sec
481 (211) 454.4 (197) 508 (233)
Total MVC 315 (25.3) 323.3 (50.8) 307.8 (31.4)
Functional performance
TUG test 8.7 (2.9) 8.1 (2.7) 9.5 (3.0)
10MWT 7.0 (1.7) 6.8 (1.9) 7.3 (1.6)
FSST 10.0 (2.7) 9.1 (2.3) 11.1 (2.9)
Abbreviations: 10MWT, 10-Meter Walk Test; ACE, angiotensin converting
enzyme; AF, atrial fibrillation; AICD, automated internal cardiac defibrilla-
tor; ARB, angiotensin II receptor blocker; BMI, body mass index; CAD,
coronary artery disease; CKD, chronic kidney disease; COMBO, Combined
Moderate-Intensity Aerobic and Resistance Training; COPD, chronic
obstructive pulmonary disease; DM, diabetes mellitus; FSST, Four Square
Step Test; HR, heart rate; HTN, hypertension; LVEF, left ventricular ejec-
tion fraction; MVC, maximum voluntary contraction; NYHA, New York
Heart Association; PPM, permanent pacemaker; PRIME, Peripheral Remo-
deling through Intermittent Muscular Exercise; TMVC, total maximum vol-
untary contraction; TUG, Time Up and Go; VO2, volume of oxygen uptake
during exercise.
aData are expressed as mean (SD) unless otherwise stated.
JAGS SEPTEMBER 2020-VOL. 68, NO. 9 PRIME-HF: EXERCISE FOR OLDER PATIENTS WITH HF 1957
(on seven occasions). Complaints related to existing mus-
culoskeletal injuries occurred in seven PRIME partici-
pants (27 occasions) and six from the COMBO group
(11 occasions).
Training Loads
Details of the weekly training loads are presented in
Table 2. By the final training week (week 8 of COMBO
training), the participants initially allocated to PRIME and
COMBO interventions were training at a weekly energy
expenditure for the aerobic component of 169.7  18.7
MET-min-wk−1 and 143.2  9.2 MET-min-wk−1, respec-
tively (P = .2), and at a volume load for the resistive compo-
nent of 9,075.7  1,015.4 kg/wk and 8,067.0  527 kg/
wk, respectively (P = .4). RPEs were balanced between
groups.
Effects of PRIME and COMBO
After 8 weeks of training, the PRIME group increased
VO2peak significantly, by 2.4 mL/kg/min (95% CI = .7-4.1;
P < .05), whereas the COMBO group showed a minimal
change of .2 mL/kg/min (95% CI = −1.5 to 1.8) (Table 2).
This produced a large between-group response effect size
(Cohen’s d) of 1.0. A clinically important improvement in
VO2peak (defined as a >6% increase
19) was observed in
60% of the PRIME group and 33% of the COMBO group
after 8 weeks of training (Figure 2B).
The VO2 at AT increased by 1.6 mL/kg/min (95%
CI = .0-3.2) in the PRIME group, whereas a negative
change (indicating a worsening of the clinical outcome) of
−1.2 mL/kg/min (95% CI = −2.9 to .4) was observed in the
COMBO group. This produced a large between-group
effect size (Cohenʼs d = 1.5; Figure 2).
Total MVC increased significantly in both the PRIME
(48.6 k; 95% CI = 7.8-89.3; P = .01) and COMBO groups
(74.6 k; 95% CI = 39.3-110.0; P < .001) in comparison
with baseline. The difference between groups produced a
moderate between-group effect size of .6 (Figure 2).
DISCUSSION
We report that (1) older patients with HFrEF can safely
perform current recommended exercise guidelines, despite
these guidelines being formulated by data from younger
cohorts, and (2) 4 weeks of PRIME before COMBO pro-
duced benefits for both aerobic power and strength,
whereas 8 weeks of COMBO training provided no increase
in aerobic power but superior strength gains. PRIME may
provide a more beneficial exercise option for older patients
with HFrEF, particularly those with both significant aerobic
capacity and strength impairments.
The widely adopted exercise recommendations for
patients with HFrEF involve moderate-intensity aerobic
exercise in combination with resistance training.3,4 These
endorsements follow the consistent demonstration of
improved functional capacity, reduced rates of hospitaliza-
tion, and improved quality of life with exercise train-
ing.3,4,7,20 As highlighted in the updated Cochrane review
of 2019, the problem remains that older patients with
HFrEF, who are often more functionally limited, are unre-
presented in clinical trials. The current study successfully
recruited a population reflective of the real-world patient,
achieving a mean age of participants of 73 years and base-
line VO2peak of 13.5 mL/kg/min.
As hypothesized, COMBO and PRIME training was
safe and well tolerated by participants, with no major
adverse events reported and an acceptable frequency of
minor events related mainly to existing musculoskeletal
injuries. The lack of improvement in VO2peak observed in
the COMBO group is not unprecedented and was also
reported in a meta-analysis of exercise training in older
patients with HF.21 Of note, the 2009 prospective trial by
Brubaker et al involving 59 patients with HFrEF (mean
age = 70.2  5.1) demonstrated that after 16 weeks the
exercise training group had 12% longer exercise time on
the bike and 13% greater exercise workload than the con-
trol group, although there was no increase in VO2peak.
22
Similarly, the HF-ACTION trial (mean age = 59 years) used
a comparable exercise intervention and demonstrated a
median increase in VO2peak of just 4% in the exercise group
compared with the control after 3 months of training.23
Combined, these findings may indicate a nonoxidative
Table 2. Effects of PRIME and COMBO Interventions on Aerobic Capacity and Muscle Strength






COMBO 13.4 (10.9 to 16.0) 13.2 (10.7 to 15.8) 13.6 (10.3 to 17.0) .2 (−1.5 to 1.8) 1.0
PRIME 13.1 (10.6 to 15.5) 14.9 (12.3 to 17.5) 15.5 (12.6 to 18.3) 2.4 (.7 to 4.1)*
VO2 at AT, mL/kg/min
COMBO 8.9 (6.9 to 10.9) 7.5 (6.4 to 8.6) 7.6 (5.7 to 9.6) −1.2 (−2.9 to .4) 1.5
PRIME 7.7 (6.7 to 8.6) 8.6 (7.5 to 9.8) 9.2 (8.0 to 10.5) 1.6 (.0 to 3.2)
Total MVC, kg
COMBO 307.8 (257.3 to 358.3) 325.2 (266.4 to 384.0) 382.4 (326.8 to 438.0) 74.6 (39.4 to 110.0)* .6
PRIME 323.3 (199 to 447.6) 359.6 (136.1 to 483.2) 374.9 (251.3 to 498.6) 48.6 (7.8 to 89.3)*
Abbreviations: AT, anaerobic threshold; COMBO, COMBined moderate-intensity aerobic and resistance training; MVC, muscle voluntary contraction;
PRIME, Peripheral Remodeling through Intermittent Muscular Exercise; VO2, volume of oxygen uptake; VO2peak, peak aerobic capacity.
*P < .05.
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muscle adaptation that may not be reflected in VO2peak
measurement.
In comparison, patients initially allocated to PRIME
training exhibited a significant improvement in VO2peak
compared with baseline. The resultant difference between
interventions (large effect size) suggests a potential superior-
ity of PRIME for measures of aerobic capacity. According
to the HF-ACTION trial, every 6% increase in VO2peak is
associated with a 5% lower risk of all-cause mortality and
all-cause hospitalization19 In this respect, initial allocation
to PRIME training was also more frequently associated
with improvements above this clinically important thresh-
old, in comparison with participants in the COMBO group
(Figure 2B; 66% vs 33% of participants). These increases
in aerobic fitness are noteworthy given that PRIME does
not include a traditional aerobic training component such
as walking or cycle training, whereas COMBO does.
For the outcome of maximal muscular strength, both
PRIME and COMBO produced statistically significant
increases from baseline; however, COMBO appeared
superior to PRIME with a moderate effect size of .6. This
finding is logical, given strength was trained with heavier
weights and lower repetitions during COMBO. Upon reflec-
tion, a measure of muscular endurance may have been a
useful additional outcome measure.
This pilot study was not powered to delineate mecha-
nisms of change with PRIME training, but we speculate that
the increases in aerobic capacity may be owing to a mitigation
Figure 2. Group mean data at baseline, 4 weeks, and 8 weeks (left column) and waterfall graphs of individual training responses from
baseline to 8 weeks to Peripheral Remodeling through Intermittent Muscular Exercise (PRIME) or COMBined moderate-intensity aer-
obic and resistance training (COMBO) treatment (right column), regarding peak aerobic capacity (VO2peak mL/kg/min) (A and B);
VO2 at Anaerobic Threshold (AT) (VO2 mL/kg/min) (C and D); and total weight lifted (total kg) (E and F). Dotted line f (tile b) indi-
cates a clinically important improvement of 6%. Values are given as mean  standard error of the mean. *Indicates moderate effect
size (Cohen’s d >.6 for between-group improvement 0-8 weeks). **Indicates large effect size (Cohen’s d >1.0 between-group improve-
ment 0-8 weeks).
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of peripheral tissue maladaptations that are primarily respon-
sible for exercise intolerance in HF according to the “muscle
hypothesis” of HF.24 By focusing initially on relatively small
peripheral muscle masses, the PRIME regime aims to provide
a localized stimulus, not restricted by compromised or com-
peting perfusion. This approach is based on earlier work that
showed increases in arm vasoreactivity and strength in both
healthy young subjects and those with CHF following hand-
grip exercise.25,26 Conceptually, this type of stimulus would
allow a higher intensity exercise in the exercising tissue bed
for longer periods than what could be achieved with whole-
body or large muscle group exercise. This may allow for
greater peripheral training adaptations that increase oxygen
extraction and metabolic efficiency, therefore partially revers-
ing exercise intolerance.
This study represents an important step in closing the
age bias seen across clinical exercise studies and has pro-
vided the impetus for the development of a larger, defini-
tively powered study. If indeed PRIME exercise is shown to
benefit older patients with HF, cardiac rehabilitation pro-
viders and policy developers need to consider how exercise
guidelines can be modified to include older patients with
HF more effectively, so that the benefits of exercise can be
offered, safely and effectively, to the full spectrum of HF
patients including older persons. It may also be useful in
other disease states where central impairments limit exercise
capacity, such as pulmonary disease.
The study has some potential limitations. First, women
represented only 20% of our study population. The misrep-
resentation of older women is encountered in clinical trials
and in cardiac rehabilitation programs, and it represents
both a failure of clinicians to refer such patients, as well as
logistic difficulties encountered by older women in attending
these programs.20,27 Furthermore, we did not include
patients with HF with preserved ejection fraction (HFpEF),
who represent approximately 50% of the HF population.28
Patients with HFpEF are usually older than those with
HFrEF and may have more peripheral limitations to exercise
tolerance.29 Future studies should include patients with both
HF subtypes and consider strategies to improve the represen-
tation of women. In addition, although Cohen’s d strongly
suggested positive effects to aerobic capacity outcomes in
favor of the PRIME group, the pilot sample size is relatively
small, and a larger powered study is required to assess accu-
rately the effects of PRIME vs COMBO exercise training.
In conclusion, among a sample of older patients with
HFrEF, we found that although traditional exercise and
PRIME exercise approaches were well tolerated, only
PRIME training produced positive changes to aerobic
capacity in conjunction with increases in muscular strength.
Taken together, these findings support the hypothesis that
PRIME may have potential advantages for older patients
with HFrEF and could be a possible alternative exercise
modality.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article.
Supplementary Figure S1: Algorithm of inclusion and
exclusion criteria. Adapted from the Exercise and Sports
Science Australia Position Statement on exercise training
and chronic heart failure.5
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